Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: peytavin g. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.
Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D; Narval (ANRS 088) Study group. Brun-Vézinet F, et al. Among authors: peytavin g. AIDS. 2003 Aug 15;17(12):1795-802. doi: 10.1097/00002030-200308150-00008. AIDS. 2003. PMID: 12891065
Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group. Vray M, et al. Among authors: peytavin g. Antivir Ther. 2003 Oct;8(5):427-34. doi: 10.1177/135965350300800510. Antivir Ther. 2003. PMID: 14640390 Clinical Trial.
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: peytavin g. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D. Delaunay C, et al. Among authors: peytavin g. J Virol. 2005 Aug;79(15):9572-8. doi: 10.1128/JVI.79.15.9572-9578.2005. J Virol. 2005. PMID: 16014919 Free PMC article. Clinical Trial.
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.
Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, Bonnet B, Yeni P, Bentata M, Michelet C, Benalycherif A, Brun Vezinet F, Miller MD, Flandre P; TONUS (IMEA 021) Study Group. Landman R, et al. Among authors: peytavin g. HIV Clin Trials. 2005 Nov-Dec;6(6):291-301. doi: 10.1310/9DQP-R7JA-75ED-RBCP. HIV Clin Trials. 2005. PMID: 16452063 Clinical Trial.
485 results